FCγRIIIA and FCγRIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma

Abstract

We investigated the association of FcγRIIIa and FcγRIIa polymorphisms and response to R-CHOP in 58 patients with diffuse large B-cell lymphoma (DLBCL). FcγRIIIa and FcγRIIa polymorphisms did not influence response, event-free or overall survival. These results suggest that ADCC via FcγIIIa and FcγRIIa may not be the major mechanism of activity of the R-CHOP combination in DLBCL.